文献速递临床试验与 GCP流行病学与生物统计组学、生物样本库与精准医学

SCRIPT试验:在基层医疗中使用多基因风险评分定制结直肠癌筛查方案的随机对照试验研究方案

The SCRIPT trial: study protocol for a randomised controlled trial of a polygenic risk score to tailor colorectal cancer screening in primary care.
PubMed 文献 · Trials · 2022-09-27

本试验旨在评估在基层医疗中实施SCRIPT干预(基于多基因风险评分的个体化结直肠癌风险报告及筛查建议)能否在12个月后提高风险适配的结直肠癌筛查率。拟纳入274名45至70岁就诊于全科医生的患者,随机分为干预组和对照组。主要结局为12个月后风险适配的筛查行为。

要点

  • SCRIPT干预包括结直肠癌多基因风险评分、风险特异性筛查建议及面向患者和全科医生的风险报告。
  • 纳入45至70岁全科就诊者,50岁以上者仅限筛查逾期者参与。
  • 主要结局为12个月后风险适配的结直肠癌筛查,采用客观卫生服务数据评估。

核心结论

  • 本试验旨在确定在基层医疗中提供的基于多基因风险评分的个体化结直肠癌风险估计能否增加风险适配的结直肠癌筛查。
  • 未来的群体风险分层结直肠癌筛查规划可在基层医疗中整合风险评估,同时鼓励遵循靶向筛查建议。

研究设计与样本

  • 随机对照试验,计划纳入274名参与者,按全科诊所分层,使用计算机生成的分配序列随机分为干预组或对照组。
  • 干预组接受SCRIPT干预,包括结直肠癌多基因风险评分、根据风险定制的筛查建议以及面向参与者和其全科医生的风险报告,均在基层医疗中实施。
  • 对照组接受标准的癌症风险降低信息。

关键数值与推荐

  • 主要结局为12个月后风险适配的结直肠癌筛查;干预组的风险适配筛查依据多基因风险评分衍生的风险定义,对照组依据家族史和国家筛查指南定义,两组均考虑既往筛查的时间、类型和结果。
  • 次要结局包括干预后1、6、12个月时的癌症特异性担忧、风险感知、结直肠癌筛查行为的预测因素、筛查意向和卫生服务使用情况。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Polygenic risk scores (PRSs) can predict the risk of colorectal cancer (CRC) and target screening more precisely than current guidelines using age and family history alone. Primary care, as a far-reaching point of healthcare and routine provider of cancer screening and risk information, may be an ideal location for their widespread implementation. METHODS: This trial aims to determine whether the SCRIPT intervention results in more risk-appropriate CRC screening after 12 months in individuals attending general practice, compared with standard cancer risk reduction information. The SCRIPT intervention consists of a CRC PRS, tailored risk-specific screening recommendations and a risk report for participants and their GP, delivered in general practice. Patients aged between 45 and 70 inclusive, attending their GP, will be approached for participation. For those over 50, only those overdue for CRC screening will be eligible to participate. Two hundred and seventy-four participants will be randomised to the intervention or control arms, stratified by general practice, using a computer-generated allocation sequence. The primary outcome is risk-appropriate CRC screening after 12 months. For those in the intervention arm, risk-appropriate screening is defined using PRS-derived risk; for those in the control arm, it is defined using family history and national screening guidelines. Timing, type and results of the previous screening are considered in both arms. Objective health service data will capture screening behaviour. Secondary outcomes include cancer-specific worry, risk perception, predictors of CRC screening behaviour, screening intentions and health service use at 1, 6 and 12 months post-intervention delivery. DISCUSSION: This trial aims to determine whether a PRS-derived personalised CRC risk estimate delivered in primary care increases risk-appropriate CRC screening. A future population risk-stratified CRC screening programme could incorporate risk assessment within primary care while encouraging adherence to targeted screening recommendations. TRIAL REGISTRATION: Australian and New Zealand Clinical Trial Registry ACTRN12621000092897p. Registered on 1 February 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Saya S, Boyd L, Chondros P, et al. The SCRIPT trial: study protocol for a randomised controlled trial of a polygenic risk score to tailor colorectal cancer screening in primary care. Trials. 2022. PMID: 36163034. doi:10.1186/s13063-022-06734-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。